NEW YORK (GenomeWeb) – Fitch Ratings yesterday affirmed Bio-Rad's debt ratings, including its issuer default rating of BBB-, citing the company's historically low leverage and its low debt load, which provides a cushion against higher expenses associated with internal projects. 

Fitch also said that Bio-Rad's rating outlook is stable.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.